Skip to content

research

Relevant Literature

Trauma

Björkholm M, Fagrell B, Przybelski R, Winslow N, Young M, Winslow R. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol. Haematologica, 90: 505-515, 2005.

Cabrales P, Tsai A, Winslow R, Intaglietta M. Extreme hemodilution with PEG-hemoglobin vs. PEG-albumin. Am J Physiol Heart Circ Physiol, 289: H2392-H2400, 2005.

Cabrales P, Tsai A, Winslow R, Intaglietta M. Effects of extreme hemodilution with hemoglobin based O2 carriers on microvascular pressure. Am J Physiol Heart Circ Physiol, 288: H2146-H2153, 2005.

Drobin D, Kjellström BT, Malm E, Malavalli A, Lohman J, Vandegriff KD, Young MA, Winslow RM.Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4). J Appl Physiol, 96: 1843 1853, 2004.

Olofsson C, Nygårds EB, Ponzer S, Fagrell B, Przybelski R, Keipert PE, Winslow N, Winslow R. A randomized, single blind, increasing dose safety trial of an oxygen-carrying plasma expander (Hemospan ®) administered to orthopedic surgery patients with spinal anesthesia. Trans Med, 18: 28-39, 2008.

Olofsson N, Ahl T, Johansson T, Larsson S, Nellgård P, Ponzer S, Fagrell B, Przybelski R, Keipert P, Winslow N, Winslow R.A multi-center clinical study of the safety and activity of maleimide-polyethylene glycol hemoglobin (Hemospan ®) in patients undergoing major orthopedic surgery. Anesthesiology, 105: 1153-1163, 2006.

Vandegriff KD, Young MA, Keipert P, Winslow RM. The safety profile of Hemospan: a new oxygen therapeutic designed using maleimide poly(ethylene) glycol conjugation to human hemoglobin. TATM, 9: 213-225, 2007.

Wettstein R, Cabrales P, Erni D, Tsai AG, Winslow RM, Intaglietta M. Resuscitation from hemorrhagic shock with MalPEG-Albumin: comparison with MalPEG-Hemoglobin. Shock, 22: 351-357, 2004.

Wettstein R, Tsai AG, Erni D, Winslow RM, Intaglietta M. Resuscitation with polyethylene glycol-modified human hemoglobin improves microcirculatory blood flow and tissue oxygenation after hemorrhagic shock in awake hamsters. Crit Care Med, 31: 1824-1830, 2003.

Winslow RM. Alternative oxygen therapeutics: products, status of clinical trials, and future prospects. Curr Hematol Rep, 2: 503-510, 2003.

Winslow RM, Lohman J, Malavalli A, Vandegriff KD. Comparison of PEG-modified albumin and hemoglobin in extreme hemodilution in the rat. J Appl Physiol, 97: 1527-1534, 2004.

Young M, Riddez L, Kjellström T, Bursell J, Winslow F, Lohman J, Winslow R. MalPEG hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine. Crit Care Med, 33:1794-1804, 2005.

Young M, Riddez L, Kjellström T, Winslow RM. Effect of MalPEG-hemoglobin (MP4) on hemodynamics and acid-base status after uncontrolled hemorrhage in anesthetized swine: Comparison with crystalloid and blood. J Trauma, 63: 1234-1244, 2007.

Sickle Cell Anemia

Johnson PC, Vandegriff KD, Tsai AG, Intaglietta M. Effect of acute hypoxia on microcirculatory and tissue oxygen levels in rat cremaster muscle. J Appl Physiol, 98: 1177 1184, 2005.

Tsai AG, Cabrales P, Winslow RM, Intaglietta M. Microvascular oxygen distribution in awake hamster window chamber model during hyperoxia. Am J Physiol Heart Circ Physiol, 285: H1537-H1545, 2003.

Tsai AG, Vandegriff KD, Intaglietta M, Winslow RM. Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics. Am J Physiol Heart Circ Physiol, 285: H1411 H1419, 2003.

Vandegriff KD. Haemoglobin-based oxygen carriers. Expert Opin Investig Drugs, 9: 1967 1984, 2000.

Vandegriff KD, Young MA, Keipert P, Winslow RM. The safety profile of Hemospan: a new oxygen therapeutic designed using maleimide poly(ethylene) glycol conjugation to human hemoglobin. TATM, 9: 213-225, 2007.

Winslow RM. Alternative oxygen therapeutics: products, status of clinical trials, and future prospects. Curr Hematol Rep, 2: 503-510, 2003.

MP4

Acharya AS, Friedman JM, Manjula BN, Intaglietta M, Tsai A, Winslow R, Malavalli A, Vandegriff K, Smith P. Enhanced molecular volume of conservatively PEGylated Hb: (SP PEG5K)6-HbA is non-hypertensive. Artif Cells Blood Substit Immobil Biotech, 33: 239-255, 2005.

Manjula BN, Tsai A, Upadhya R, Perumalsamy K, Smith PK, Malavalli A, Vandegriff KD, Winslow RM, Intaglietta M, Prabhakaran M, Friedman JM, Acharya AS. Site-specific PEGylation of hemoglobin at Cys-93(β): correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain. Bioconj Chem, 14: 464 472, 2003.

McCarthy MR, Vandegriff KD, Winslow RM. The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: implications for the design of hemoglobin-based oxygen carriers. Biophys Chem, 92: 103-117, 2001.

Svergun D, Ekström F, Vandegriff KD, Malavalli A, Baker DA, Nilsson C, Winslow RM. Solution structure of poly(ethylene) glycol-conjugated hemoglobin revealed by small-angle x-ray scattering: implications for a new oxygen therapeutic. Biophys J, 94: 173-181, 2008.

Tsai AG, Cabrales P, Acharya S, Manjula BN, Winslow RM, Intaglietta M. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood, 108: 3603-3610, 2006.

Tsai AG, Vandegriff KD, Intaglietta M, Winslow RM. Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics. Am J Physiol Heart Circ Physiol, 285: H1411 H1419, 2003.

Vandegriff KD, Bellelli A, Samaja M, Malavalli A, Brunori M, Winslow RM. Kinetics of NO and O2 binding to a maleimide polyethylene glycol-conjugated human hemoglobin. Biochem J, 382: 183-189, 2004.

Vandegriff KD, Malavalli A, Mann C, Jiang E, Lohman J, Young MA, Samaja M, Winslow RM. Oxidation and haem loss kinetics of poly(ethylene glycol)-conjugated hemoglobin (MP4): dissociation between in vitro and in vivo oxidation rates. Biochem J, 399: 463-471, 2006.

Vandegriff KD, Malavalli A, Wooldridge J, Lohman J, Winslow RM. MP4, a new nonvasoactive PEG-Hb conjugate. Transfusion, 43: 509-516, 2003.

Vandegriff KD. Haemoglobin-based oxygen carriers. Expert Opin Investig Drugs, 9: 1967 1984, 2000.

Winslow R. The role of P50 in tissue oxygen delivery by cell-free oxygen carriers. In: Kobayashi K, Tsuchida E, Horinouchi H, eds. Artifical Oxygen Carrier: Its Front Line. Tokyo: Springer-Verlag Tokyo, pp. 38-52, 2006.

Winslow R. Targeted O2 delivery by low-p50 hemoglobin: a new basis for hemoglobin-based oxygen carriers. Artif Cells Blood Substit Immobil Biotech, 33: 1-12, 2005.

Winslow R. Oxygen transport agents:  a new approach to red blood cell alternatives. TATM, 5: 498-504, 2004.

Winslow RM and Intaglietta M. Red cell age and loss of function: advance or SNO-job? Transfusion, 48: 411-414, 2008.

Winslow RM. MP4, a new nonvasoactive polyethylene glycol-hemoglobin conjugate. Artif Organs, 28: 800-806, 2004.

Winslow RM. Hemospan: scientific foundations and clinical development. ISBT Science Series, 1: 161-166, 2006.

Young MA, Malavalli A, Winslow N, Vandegriff KD, Winslow RM. Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys. Translational Res, 149: 333-342, 2007.